Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497662 | 0.90 | GPR119 (1.00) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4502123 | 0.88 | GPR119 (0.79) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL11389749 | 0.88 | GPR119 (0.79) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4479826 | 0.87 | GPR119 (0.76) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4501147 | 0.87 | GPR119 (0.76) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4479827 | 0.87 | GPR119 (0.76) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4492721 | 0.87 | GPR119 (0.76) | GPR119CYP2C9 | |
| SCHEMBL4492211 | 0.86 | GPR119 (0.76) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4497235 | 0.86 | GPR119 (0.75) | GPR119CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL11392613 | 0.85 | GPR119 (0.74) | GPR119CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | claimed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | claimed |
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GPR119 1/4885CYP2C9 971/4885CYP3A4 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.